Multifunctional nanopolymers for blood–brain barrier delivery and inhibition of glioblastoma growth through egfr/egfrviii, c-myc, and pd-1

Keyphrases

• Programmed Death-ligand 1 (PD-L1) 100%
• Glioblastoma 100%
• C-Myc 100%
• Egfr 100%
• Blood-brain Barrier Delivery 100%
• Nanopolymers 100%
• EGFRvIII 100%
• Antisense Oligonucleotides 40%
• Clinical Practice 20%
• Disulfide Bond 20%
• Central Nervous System 20%
• New Therapeutic Approaches 20%
• Tumor 20%
• Tyrosine Kinase 20%
• Tumor Growth 20%
• Blood-brain Barrier 20%
• Monoclonal Antibody 20%
• Adult Population 20%
• Combination Therapy 20%
• Brain Tumor 20%
• Biopolymers 20%
• Pediatric Population 20%
• Checkpoint Inhibitors 20%
• Protein Synthesis 20%
• Anticancer 20%
• Molecular Markers 20%
• Membrane Receptors 20%
• Glioblastoma Cells 20%
• AP-2 20%
• Nuclear Transcription Factor 20%
• Tumor-bearing Animals 20%
• Malonic Acid 20%
• Primary Brain Cancer 20%
• Morpholino Antisense Oligonucleotide 20%
• Anticancer Inhibitors 20%
• Anti-PD-1 Antibody 20%
• Multifunctional Nanomedicine 20%
• Functional Moieties 20%
• Naturally-derived 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Glioblastoma 100%
• Antisense Oligonucleotide 60%
• Epidermal Growth Factor Receptor 40%
• Mouse 20%
• Biopolymer 20%
• Molecular Marker 20%
• Protein Tyrosine Kinase 20%
• Tumor Growth 20%
• Brain Cancer 20%
• Malic Acid 20%
• Neoplasm 20%
• Transcription Factors 20%
• Combination Therapy 20%
• Nanomedicine 20%
• Monoclonal Antibody 20%
• Brain Tumor 20%
• Disulfide Bond 20%